5829 related articles for article (PubMed ID: 2683997)
1. Immunosuppression by melanoma cells as a factor in the generation of metastatic disease.
Cochran AJ; Wen DR; Farzad Z; Stene MA; McBride W; Lana AM; Hoon DS; Morton DL
Anticancer Res; 1989; 9(4):859-64. PubMed ID: 2683997
[TBL] [Abstract][Full Text] [Related]
2. Zoned immune suppression of lymph nodes draining malignant melanoma: histologic and immunohistologic studies.
Cochran AJ; Pihl E; Wen DR; Hoon DS; Korn EL
J Natl Cancer Inst; 1987 Mar; 78(3):399-405. PubMed ID: 3469453
[TBL] [Abstract][Full Text] [Related]
3. Suppressor cell activity in melanoma-draining lymph nodes.
Hoon DS; Bowker RJ; Cochran AJ
Cancer Res; 1987 Mar; 47(6):1529-33. PubMed ID: 2949828
[TBL] [Abstract][Full Text] [Related]
4. Lymphocyte subset alterations in nodes regional to human melanoma.
Farzad Z; Cochran AJ; McBride WH; Gray JD; Wong V; Morton DL
Cancer Res; 1990 Jun; 50(12):3585-8. PubMed ID: 1692763
[TBL] [Abstract][Full Text] [Related]
5. Variations in functional immunocompetence of individual tumor-draining lymph nodes in humans.
Hoon DS; Korn EL; Cochran AJ
Cancer Res; 1987 Mar; 47(6):1740-4. PubMed ID: 3493068
[TBL] [Abstract][Full Text] [Related]
6. Tumor-specific CD8+ T cell reactivity in the sentinel lymph node of GM-CSF-treated stage I melanoma patients is associated with high myeloid dendritic cell content.
Vuylsteke RJ; Molenkamp BG; van Leeuwen PA; Meijer S; Wijnands PG; Haanen JB; Scheper RJ; de Gruijl TD
Clin Cancer Res; 2006 May; 12(9):2826-33. PubMed ID: 16675577
[TBL] [Abstract][Full Text] [Related]
7. Effect of melanoma on immune function in the regional lymph node basin.
Negin B; Panka D; Wang W; Siddiqui M; Tawa N; Mullen J; Tahan S; Mandato L; Polivy A; Mier J; Atkins M
Clin Cancer Res; 2008 Feb; 14(3):654-9. PubMed ID: 18245524
[TBL] [Abstract][Full Text] [Related]
8. Sentinel node biopsy and cytokeratin staining for the accurate staging of 478 breast cancer patients.
Pendas S; Dauway E; Cox CE; Giuliano R; Ku NN; Schreiber RH; Reintgen DS
Am Surg; 1999 Jun; 65(6):500-5; discussion 505-6. PubMed ID: 10366202
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibody-defined phenotypes of regional lymph node and peripheral blood lymphocyte subpopulations in early breast cancer.
Morton BA; Ramey WG; Paderon H; Miller RE
Cancer Res; 1986 Apr; 46(4 Pt 2):2121-6. PubMed ID: 3081262
[TBL] [Abstract][Full Text] [Related]
10. Regional lymphatic immunity in melanoma.
Grotz TE; Mansfield AS; Jakub JW; Markovic SN
Melanoma Res; 2012 Feb; 22(1):9-18. PubMed ID: 22082957
[TBL] [Abstract][Full Text] [Related]
11. [Evaluation of T- and B-cell immunity of regional lymph nodes in patients with skin melanoma and prognosis of the disease].
Serov AA; Kadagidze ZG
Vopr Onkol; 1983; 29(12):18-20. PubMed ID: 6607569
[TBL] [Abstract][Full Text] [Related]
12. Natural killer cell activity in tumor-draining lymph nodes: investigations in patients with malignant melanoma and head and neck cancer.
Micksche M; Vinzenz K; Kokoschka EM; Kokoschka R
Nat Immun Cell Growth Regul; 1985; 4(6):315-27. PubMed ID: 4088287
[TBL] [Abstract][Full Text] [Related]
13. CXC chemokine receptor 3 expression by activated CD8+ T cells is associated with survival in melanoma patients with stage III disease.
Mullins IM; Slingluff CL; Lee JK; Garbee CF; Shu J; Anderson SG; Mayer ME; Knaus WA; Mullins DW
Cancer Res; 2004 Nov; 64(21):7697-701. PubMed ID: 15520172
[TBL] [Abstract][Full Text] [Related]
14. Immune responses in the draining lymph nodes against cancer: implications for immunotherapy.
Shu S; Cochran AJ; Huang RR; Morton DL; Maecker HT
Cancer Metastasis Rev; 2006 Jun; 25(2):233-42. PubMed ID: 16770535
[TBL] [Abstract][Full Text] [Related]
15. [In situ analysis of distribution of immunocompetent cells in tumor's local draining lymph nodes].
Chen XL; He JJ; Chen K; Lai BC; Si LS; Wang YL
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2006 Nov; 22(6):748-51. PubMed ID: 17077016
[TBL] [Abstract][Full Text] [Related]
16. Analysis of a natural immune response against tumor antigens in a melanoma survivor: lessons applicable to clinical trial evaluations.
Yamshchikov G; Thompson L; Ross WG; Galavotti H; Aquila W; Deacon D; Caldwell J; Patterson JW; Hunt DF; Slingluff CL
Clin Cancer Res; 2001 Mar; 7(3 Suppl):909s-916s. PubMed ID: 11300491
[TBL] [Abstract][Full Text] [Related]
17. Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for alpha1,3galactosyltransferase.
LaTemple DC; Abrams JT; Zhang SY; Galili U
Cancer Res; 1999 Jul; 59(14):3417-23. PubMed ID: 10416604
[TBL] [Abstract][Full Text] [Related]
18. Plasmacytoid dendritic cells represent a major dendritic cell subset in sentinel lymph nodes of melanoma patients and accumulate in metastatic nodes.
Gerlini G; Urso C; Mariotti G; Di Gennaro P; Palli D; Brandani P; Salvadori A; Pimpinelli N; Reali UM; Borgognoni L
Clin Immunol; 2007 Nov; 125(2):184-93. PubMed ID: 17827069
[TBL] [Abstract][Full Text] [Related]
19. Regional lymph node dissections in malignant melanoma.
Lawton GP; Ariyan S
Clin Plast Surg; 2000 Jul; 27(3):431-40, ix. PubMed ID: 10941563
[TBL] [Abstract][Full Text] [Related]
20. Criteria in sentinel lymph nodes of melanoma patients that predict involvement of nonsentinel lymph nodes.
Satzger I; Völker B; Meier A; Kapp A; Gutzmer R
Ann Surg Oncol; 2008 Jun; 15(6):1723-32. PubMed ID: 18389323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
